| Year |
Citation |
Score |
| 2024 |
Gu H, Chen C, Hou ZS, He XD, Xie S, Ni J, Qian C, Cheng X, Jiang T, Yang C, Roberts TM, Zheng J, Varner JA, Armstrong SA, Zhao JJ. PI3Kγ maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway. Blood. PMID 38271660 DOI: 10.1182/blood.2023022202 |
0.324 |
|
| 2023 |
Tubío-Santamaría N, Jayavelu AK, Schnoeder TM, Eifert T, Hsu CJ, Perner F, Zhang Q, Wenge DV, Hansen FM, Kirkpatrick JM, Jyotsana N, Lane SW, von Eyss B, Deshpande AJ, Kühn MWM, ... ... Armstrong SA, et al. Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia. Molecular Cancer. 22: 196. PMID 38049829 DOI: 10.1186/s12943-023-01907-7 |
0.348 |
|
| 2023 |
Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, Thirman MJ, Patel MR, Dickens DS, Shenoy S, Shukla N, Kantarjian H, Armstrong SA, Perner F, Perry JA, et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. PMID 36922593 DOI: 10.1038/s41586-023-05812-3 |
0.331 |
|
| 2022 |
Uckelmann HJ, Haarer EL, Takeda R, Wong EM, Hatton C, Marinaccio C, Perner F, Rajput M, Antonissen NJC, Wen Y, Yang L, Brunetti L, Chen CW, Armstrong SA. Mutant NPM1 directly regulates oncogenic transcription in acute myeloid leukemia. Cancer Discovery. PMID 36455613 DOI: 10.1158/2159-8290.CD-22-0366 |
0.388 |
|
| 2022 |
Soto-Feliciano YM, Sanchez-Rivera FJ, Perner F, Barrows DW, Kastenhuber ER, Ho YJ, Carroll TS, Xiong Y, Anand D, Soshnev AA, Gates L, Beytagh MC, Cheon D, Gu SS, Liu XS, ... ... Armstrong SA, et al. A molecular switch between mammalian MLL complexes dictates response to Menin-MLL inhibition. Cancer Discovery. PMID 36264143 DOI: 10.1158/2159-8290.CD-22-0416 |
0.3 |
|
| 2022 |
Aubrey BJ, Cutler JA, Bourgeois W, Donovan KA, Gu S, Hatton C, Perlee S, Perner F, Rahnamoun H, Theall ACP, Henrich JA, Zhu Q, Nowak RP, Kim YJ, Parvin S, ... ... Armstrong SA, et al. IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia. Nature Cancer. PMID 35534777 DOI: 10.1038/s43018-022-00366-1 |
0.348 |
|
| 2021 |
Heikamp EB, Henrich JA, Perner F, Wong EM, Hatton C, Wen Y, Barwe SP, Gopalakrishnapillai A, Xu H, Uckelmann HJ, Takao S, Kazansky Y, Pikman Y, McGeehan GM, Kolb EA, ... Armstrong SA, et al. The Menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML. Blood. PMID 34582559 DOI: 10.1182/blood.2021012806 |
0.389 |
|
| 2021 |
Perner F, Schnoeder TM, Xiong Y, Jayavelu AK, Mashamba N, Santamaria NT, Huber N, Todorova K, Hatton C, Perner B, Eifert T, Murphy C, Hartmann M, Hoell JI, Schröder N, ... Armstrong SA, et al. YBX1 mediates translation of oncogenic transcripts to control cell competition in AML. Leukemia. PMID 34465866 DOI: 10.1038/s41375-021-01393-0 |
0.381 |
|
| 2020 |
Cai SF, Chu SH, Goldberg AD, Parvin S, Koche RP, Glass JL, Stein EM, Tallman MS, Sen F, Famulare CA, Cusan M, Huang CH, Chen CW, Zou L, Cordner KB, ... ... Armstrong SA, et al. Leukemia cell of origin influences apoptotic priming and sensitivity to LSD1 inhibition. Cancer Discovery. PMID 32606137 DOI: 10.1158/2159-8290.Cd-19-1469 |
0.435 |
|
| 2020 |
Dzama MM, Steiner M, Rausch J, Sasca D, Schönfeld J, Kunz K, Taubert MC, McGeehan GM, Chen CW, Mupo A, Hähnel PS, Theobald M, Kindler T, Koche RP, Vassiliou GS, ... Armstrong SA, et al. Synergistic Targeting of FLT3 Mutations in AML via Combined Menin-MLL and FLT3 Inhibition. Blood. PMID 32589720 DOI: 10.1182/Blood.2020005037 |
0.418 |
|
| 2020 |
Perner F, Gadrey JY, Xiong Y, Hatton C, Eschle BK, Weiss A, Stauffer F, Gaul C, Tiedt R, Perry JA, Armstrong SA, Krivtsov AV. Novel Inhibitors of the Histone-Methyltransferase DOT1L Show Potent Antileukemic Activity in Patient-derived Xenografts. Blood. PMID 32575123 DOI: 10.1182/Blood.2020006113 |
0.309 |
|
| 2020 |
Uckelmann HJ, Armstrong SA. Chromatin Complexes Maintain Self-Renewal of Myeloid Progenitors in AML: Opportunities for Therapeutic Intervention. Stem Cell Reports. PMID 32559456 DOI: 10.1016/J.Stemcr.2020.05.013 |
0.492 |
|
| 2020 |
Olsen SN, Armstrong SA. It's Not What You Say But How You Say It: Targeting RNA Methylation in AML. Molecular Cell. 78: 996-998. PMID 32559428 DOI: 10.1016/J.Molcel.2020.05.027 |
0.315 |
|
| 2020 |
Hemming ML, Fan C, Raut CP, Demetri GD, Armstrong SA, Sicinska E, George S. Oncogenic gene expression programs in leiomyosarcoma and characterization of conventional, inflammatory and uterogenic subtypes. Molecular Cancer Research : McR. PMID 32518213 DOI: 10.1158/1541-7786.Mcr-20-0197 |
0.392 |
|
| 2020 |
Uckelmann HJ, Kim SM, Wong EM, Hatton C, Giovinazzo H, Gadrey JY, Krivtsov AV, Rücker FG, Döhner K, McGeehan GM, Levine RL, Bullinger L, Vassiliou GS, Armstrong SA. Therapeutic targeting of preleukemia cells in a mouse model of mutant acute myeloid leukemia. Science (New York, N.Y.). 367: 586-590. PMID 32001657 DOI: 10.1126/Science.Aax5863 |
0.436 |
|
| 2019 |
Krivtsov AV, Evans K, Gadrey JY, Eschle BK, Hatton C, Uckelmann HJ, Ross KN, Perner F, Olsen SN, Pritchard T, McDermott L, Jones CD, Jing D, Braytee A, Chacon D, ... ... Armstrong SA, et al. A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. Cancer Cell. 36: 660-673.e11. PMID 31821784 DOI: 10.1016/J.Ccell.2019.11.001 |
0.404 |
|
| 2019 |
Cremer A, Ellegast JM, Alexe G, Frank ES, Ross L, Chu SH, Pikman Y, Robichaud A, Goodale A, Haupl B, Mohr S, Rao AV, Walker A, Blachly JS, Piccioni F, ... Armstrong SA, et al. Resistance mechanisms to SYK inhibition in acute myeloid leukemia. Cancer Discovery. PMID 31771968 DOI: 10.1158/2159-8290.Cd-19-0209 |
0.357 |
|
| 2019 |
Boettcher S, Miller PG, Sharma R, McConkey M, Leventhal M, Krivtsov AV, Giacomelli AO, Wong W, Kim J, Chao S, Kurppa KJ, Yang X, Milenkowic K, Piccioni F, Root DE, ... ... Armstrong SA, et al. A dominant-negative effect drives selection of missense mutations in myeloid malignancies. Science (New York, N.Y.). 365: 599-604. PMID 31395785 DOI: 10.1126/Science.Aax3649 |
0.342 |
|
| 2019 |
Hurtz C, Chan LN, Geng H, Ballabio E, Xiao G, Deb G, Khoury H, Chen CW, Armstrong SA, Chen J, Ernst P, Melnick A, Milne T, Müschen M. Rationale for targeting BCL6 in -rearranged acute lymphoblastic leukemia. Genes & Development. PMID 31395741 DOI: 10.1101/Gad.327593.119 |
0.425 |
|
| 2019 |
Barbosa K, Deshpande A, Chen BR, Ghosh A, Sun Y, Dutta S, Weetall M, Dixon J, Armstrong SA, Bohlander SK, Deshpande AJ. Acute Myeloid Leukemia Driven by the CALM-AF10 Fusion Gene is Dependent on BMI1. Experimental Hematology. PMID 31022428 DOI: 10.1016/J.Exphem.2019.04.003 |
0.436 |
|
| 2019 |
Brien GL, Stegmaier K, Armstrong SA. Targeting chromatin complexes in fusion protein-driven malignancies. Nature Reviews. Cancer. PMID 30962549 DOI: 10.1038/S41568-019-0132-X |
0.404 |
|
| 2019 |
Hemming ML, Lawlor MA, Andersen JL, Hagan T, Chipashvili O, Scott TG, Raut CP, Sicinska E, Armstrong SA, Demetri GD, Bradner JE. Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and are Targetable by BET Bromodomain Inhibition. Cancer Research. PMID 30630822 DOI: 10.1158/0008-5472.Can-18-1888 |
0.418 |
|
| 2019 |
Chan AKN, Delaney CD, Yang L, Chang W, Miyashita K, Liu Q, Pokharel SP, Armstrong SA, Chen CD. Tudor Domain-Focused CRISPR Dropout Screen Identifies SGF29 As a Novel Essential Gene in MLL-Rearranged Leukemias Blood. 134: 530-530. DOI: 10.1182/blood-2019-131467 |
0.333 |
|
| 2019 |
Dzama MM, Taubert MC, Kunz K, Rausch J, Chen CD, Mupo A, Hähnel P, Theobald M, Kindler T, Koche RP, Vassiliou GS, Armstrong SA, Kühn MW. Combined Targeting of the Menin-MLL1 Chromatin Complex and FLT3 As a Novel Therapeutic Concept Against NPM1 Mutant or MLL-Rearranged AML with Mutated FLT3 Blood. 134: 1441-1441. DOI: 10.1182/blood-2019-122847 |
0.358 |
|
| 2019 |
Dzama MM, Taubert MC, Kunz K, Rausch J, Chen C, Mupo A, Theobald M, Kindler T, Koche RP, Vassiliou GS, Armstrong SA, Kühn MW. Abstract 3841: Therapeutic targeting ofFLT3mutations in AML via menin-MLL1 and FLT3 inhibition Cancer Research. 79: 3841-3841. DOI: 10.1158/1538-7445.Am2019-3841 |
0.441 |
|
| 2018 |
Park SM, Cho H, Thornton AM, Barlowe TS, Chou T, Chhangawala S, Fairchild L, Taggart J, Chow A, Schurer A, Gruet A, Witkin MD, Kim JH, Shevach EM, Krivtsov A, ... Armstrong SA, et al. IKZF2 Drives Leukemia Stem Cell Self-Renewal and Inhibits Myeloid Differentiation. Cell Stem Cell. PMID 30472158 DOI: 10.1016/J.Stem.2018.10.016 |
0.478 |
|
| 2018 |
Brien GL, Remillard D, Shi J, Hemming ML, Chabon J, Wynne K, Dillon ET, Cagney G, Van Mierlo G, Baltissen MP, Vermeulen M, Qi J, Fröhling S, Gray NS, Bradner JE, ... ... Armstrong SA, et al. Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. Elife. 7. PMID 30431433 DOI: 10.7554/Elife.41305 |
0.42 |
|
| 2018 |
Sun Y, Zhou B, Mao F, Xu J, Miao H, Zou Z, Phuc Khoa LT, Jang Y, Cai S, Witkin M, Koche R, Ge K, Dressler GR, Levine RL, Armstrong SA, et al. HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis. Cancer Cell. PMID 30270123 DOI: 10.1016/J.Ccell.2018.08.018 |
0.461 |
|
| 2018 |
Chu SH, Song EJ, Chabon JR, Minehart J, Matovina CN, Makofske JL, Frank ES, Ross K, Koche RP, Feng Z, Xu H, Krivtsov A, Nussenzweig A, Armstrong SA. Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by and activated . Blood Advances. 2: 2478-2490. PMID 30266823 DOI: 10.1182/Bloodadvances.2018021592 |
0.396 |
|
| 2018 |
Uckelmann HJ, Armstrong SA, Stone RM. Location, Location, Location: Mutant NPM1c Cytoplasmic Localization Is Required to Maintain Stem Cell Genes in AML. Cancer Cell. 34: 355-357. PMID 30205041 DOI: 10.1016/J.Ccell.2018.08.013 |
0.433 |
|
| 2018 |
Hemming ML, Lawlor MA, Zeid R, Lesluyes T, Fletcher JA, Raut CP, Sicinska ET, Chibon F, Armstrong SA, Demetri GD, Bradner JE. Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome. Proceedings of the National Academy of Sciences of the United States of America. PMID 29866822 DOI: 10.1073/Pnas.1802079115 |
0.364 |
|
| 2018 |
Hoshii T, Cifani P, Feng Z, Huang CH, Koche R, Chen CW, Delaney CD, Lowe SW, Kentsis A, Armstrong SA. A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage Response. Cell. 172: 1007-1021.e17. PMID 29474905 DOI: 10.1016/J.Cell.2018.01.032 |
0.374 |
|
| 2018 |
Cusan M, Cai SF, Mohammad HP, Krivtsov A, Chramiec A, Loizou E, Witkin MD, Smitheman KN, Tenen DG, Ye M, Will B, Steidl U, Kruger RG, Levine RL, Rienhoff HY, ... ... Armstrong SA, et al. LSD1 inhibition exerts its anti-leukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML. Blood. PMID 29453291 DOI: 10.1182/Blood-2017-09-807024 |
0.45 |
|
| 2018 |
Brown FC, Still E, Koche RP, Yim CY, Takao S, Cifani P, Reed C, Gunasekera S, Ficarro SB, Romanienko P, Mark W, McCarthy C, de Stanchina E, Gonen M, Seshan V, ... ... Armstrong SA, et al. MEF2C phosphorylation is required for chemotherapy resistance in acute myeloid leukemia. Cancer Discovery. PMID 29431698 DOI: 10.1158/2159-8290.Cd-17-1271 |
0.39 |
|
| 2018 |
Ramaswamy K, Forbes L, Minuesa G, Gindin T, Brown F, Kharas MG, Krivtsov AV, Armstrong SA, Still E, de Stanchina E, Knoechel B, Koche R, Kentsis A. Peptidomimetic blockade of MYB in acute myeloid leukemia. Nature Communications. 9: 110. PMID 29317678 DOI: 10.1038/s41467-017-02618-6 |
0.473 |
|
| 2018 |
Brien GL, Remillard D, Shi J, Hemming ML, Chabon J, Wynne K, Dillon ET, Cagney G, Mierlo GV, Baltissen MP, Vermeulen M, Qi J, Fröhling S, Gray NS, Bradner JE, ... ... Armstrong SA, et al. Author response: Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma Elife. DOI: 10.7554/Elife.41305.044 |
0.345 |
|
| 2018 |
Spitzer B, Gundem G, Farnoud N, Millard N, McGovern E, Patel M, Levine M, Medina J, Zhou Y, Arango Ossa JE, Walsh MF, Levine RL, Cheung IY, Armstrong SA, Cheung NV, et al. Early Detection and Molecular Characterization of Therapy-Related Leukemia in Children Reveals Patterns of Disease Transformation and Guides Future Surveillance Protocols Blood. 132: 291-291. DOI: 10.1182/Blood-2018-99-120005 |
0.36 |
|
| 2018 |
Chen B, Deshpande A, Kleppe M, Yeddula N, Yoh S, Armstrong SA, Levine RL, Chanda S, Deshpande AJ. Genomic and Proteomic Profiling of AF10-Fusion Oncoproteins Reveal Mechanisms of Leukemogenesis and Actionable Targets Blood. 132: 544-544. DOI: 10.1182/Blood-2018-99-119210 |
0.432 |
|
| 2018 |
Barbosa KO, Ghosh A, Deshpande A, Dutta S, Armstrong SA, Bohlander SK, Deshpande AJ. Genetic or Pharmacological Inhibition of the Polycomb Group Protein BMI1 Impairs Leukemic Transformation Mediated By the CALM-AF10 Fusion Oncoprotein Blood. 132: 762-762. DOI: 10.1182/Blood-2018-99-115552 |
0.442 |
|
| 2018 |
Deshpande A, Chen B, Ramezani-Rad P, Pastore A, Zhao L, Weigert O, Armstrong SA, Rickert RC, Ren B, Deshpande AJ. Targeting MYC-Driven B-Cell Lymphoma By Inhibition of the Histone Methyltransferase DOT1L Blood. 132: 2839-2839. DOI: 10.1182/Blood-2018-99-115475 |
0.433 |
|
| 2018 |
Park S, Cho H, Thornton A, Barlowe TS, Chou T, Chhangawala S, Fairchild L, Chow A, Taggart J, Schurer A, Gruet A, Witkin M, Kim JH, Shevach E, Krivstov A, Armstrong SA, et al. IKZF2 Drives Self-Renewal and Blocks Myeloid Differentiation Programs in Myeloid Leukemic Stem Cells Blood. 132: 3881-3881. DOI: 10.1182/Blood-2018-99-115034 |
0.484 |
|
| 2018 |
Chu SH, Chabon J, Minehart J, Matovina CN, Zhang J, Chen B, Callen-Moreu E, Hung PJ, Feng Z, Koche R, Liu XS, Chaudhuri J, Nussenzweig A, Sleckman B, Armstrong SA. The Lysine Histone Methyltransferase SETD2 Is Required for Appropriate Immunoglobulin VDJ Recombination Blood. 132: 511-511. DOI: 10.1182/Blood-2018-99-111952 |
0.417 |
|
| 2018 |
Uckelmann HJ, Kim SM, Antonissen NJC, Krivtsov AV, Hatton C, McGeehan GM, Levine RL, Vassiliou GS, Armstrong SA. MLL-Menin Inhibition Reverses Pre-Leukemic Progenitor Self-Renewal Induced By NPM1 Mutations and Prevents AML Development Blood. 132: 546-546. DOI: 10.1182/Blood-2018-99-110851 |
0.466 |
|
| 2018 |
Krivtsov AV, Eschle BK, Witkin M, Gadrey JY, Uckelmann HJ, Kitajima S, McGeehan GM, Armstrong SA. Abstract 4958: VTP50469 is a novel, orally available menin-MLL1 inhibitor effective against MLL-rearranged and NPM1-mutant leukemia Cancer Research. 78: 4958-4958. DOI: 10.1158/1538-7445.Am2018-4958 |
0.46 |
|
| 2017 |
Mar BG, Chu SH, Kahn JD, Krivstov AV, Koche R, Castellano CA, Kotlier JL, Zon RL, McConkey ME, Chabon J, Chappell R, Grauman PV, Hsieh JJ, Armstrong SA, Ebert BL. SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia. Blood. PMID 29018079 DOI: 10.1182/Blood-2017-03-775569 |
0.346 |
|
| 2017 |
Khalaj M, Woolthuis CM, Hu W, Durham BH, Chu SH, Qamar S, Armstrong SA, Park CY. miR-99 regulates normal and malignant hematopoietic stem cell self-renewal. The Journal of Experimental Medicine. PMID 28733386 DOI: 10.1084/Jem.20161595 |
0.307 |
|
| 2017 |
Wang SP, Tang Z, Chen CW, Shimada M, Koche RP, Wang LH, Nakadai T, Chramiec A, Krivtsov AV, Armstrong SA, Roeder RG. A UTX-MLL4-p300 Transcriptional Regulatory Network Coordinately Shapes Active Enhancer Landscapes for Eliciting Transcription. Molecular Cell. 67: 308-321.e6. PMID 28732206 DOI: 10.1016/J.Molcel.2017.06.028 |
0.346 |
|
| 2017 |
Henssen AG, Koche R, Zhuang J, Jiang E, Reed C, Eisenberg A, Still E, MacArthur IC, Rodríguez-Fos E, Gonzalez S, Puiggròs M, Blackford AN, Mason CE, de Stanchina E, Gönen M, ... ... Armstrong SA, et al. PGBD5 promotes site-specific oncogenic mutations in human tumors. Nature Genetics. PMID 28504702 DOI: 10.1038/Ng.3866 |
0.351 |
|
| 2017 |
Vu LP, Prieto C, Amin EM, Chhangawala S, Krivtsov A, Calvo-Vidal MN, Chou T, Chow A, Minuesa G, Park SM, Barlowe TS, Taggart J, Tivnan P, Deering RP, Chu LP, ... ... Armstrong SA, et al. Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. Nature Genetics. PMID 28436985 DOI: 10.1038/Ng.3854 |
0.461 |
|
| 2017 |
Remillard D, Buckley DL, Paulk J, Brien GL, Sonnett M, Seo HS, Dastierdi S, Wühr M, Dhe-Paganon S, Armstrong SA, Bradner JE. Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands. Angewandte Chemie (International Ed. in English). PMID 28418626 DOI: 10.1002/Anie.201611281 |
0.322 |
|
| 2017 |
Toska E, Osmanbeyoglu HU, Castel P, Chan C, Hendrickson RC, Elkabets M, Dickler MN, Scaltriti M, Leslie CS, Armstrong SA, Baselga J. PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. Science (New York, N.Y.). 355: 1324-1330. PMID 28336670 DOI: 10.1126/Science.Aah6893 |
0.32 |
|
| 2017 |
Ajore R, Raiser D, McConkey M, Jöud M, Boidol B, Mar B, Saksena G, Weinstock DM, Armstrong S, Ellis SR, Ebert BL, Nilsson B. Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations. Embo Molecular Medicine. PMID 28264936 DOI: 10.15252/Emmm.201606660 |
0.383 |
|
| 2017 |
Krivtsov AV, Hoshii T, Armstrong SA. Mixed-Lineage Leukemia Fusions and Chromatin in Leukemia. Cold Spring Harbor Perspectives in Medicine. PMID 28242784 DOI: 10.1101/Cshperspect.A026658 |
0.428 |
|
| 2017 |
Wan L, Wen H, Li Y, Lyu J, Xi Y, Hoshii T, Joseph JK, Wang X, Loh YE, Erb MA, Souza AL, Bradner JE, Shen L, Li W, Li H, ... ... Armstrong SA, et al. ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia. Nature. PMID 28241141 DOI: 10.1038/Nature21687 |
0.454 |
|
| 2017 |
Valerio DG, Xu H, Chen CW, Hoshii T, Eisold ME, Delaney C, Cusan M, Deshpande AJ, Huang CH, Lujambio A, Zheng YG, Zuber J, Pandita TK, Lowe SW, Armstrong SA. Histone acetyltransferase activity of MOF is required for MLL-AF9 leukemogenesis. Cancer Research. PMID 28202522 DOI: 10.1158/0008-5472.Can-16-2374 |
0.464 |
|
| 2017 |
Vu L, Prieto C, Amin EM, Minuesa G, Chhangawala S, Vidal MC, Krivtsov A, Chou T, Chow A, Barlowe T, Taggart J, Tivnan P, Deering RP, Chu LP, Gonen M, ... Armstrong S, et al. Abstract IA13: RNA regulators and the control of self-renewal Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Hemmal17-Ia13 |
0.483 |
|
| 2016 |
Xu H, Valerio DG, Eisold ME, Sinha A, Koche RP, Hu W, Chen CW, Chu SH, Brien GL, Park CY, Hsieh JJ, Ernst P, Armstrong SA. NUP98 Fusion Proteins Interact with the NSL and MLL1 Complexes to Drive Leukemogenesis. Cancer Cell. PMID 27889185 DOI: 10.1016/J.Ccell.2016.10.019 |
0.435 |
|
| 2016 |
Guryanova OA, Shank K, Spitzer B, Luciani L, Koche RP, Garrett-Bakelman FE, Ganzel C, Durham BH, Mohanty A, Hoermann G, Rivera SA, Chramiec AG, Pronier E, Bastian L, Keller MD, ... ... Armstrong SA, et al. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. Nature Medicine. PMID 27841873 DOI: 10.1038/Nm.4210 |
0.391 |
|
| 2016 |
Valerio DG, Xu H, Eisold ME, Woolthuis CM, Pandita TK, Armstrong SA. Histone acetyltransferase activity of MOF is required for adult, but not early fetal hematopoiesis in mice. Blood. PMID 27827827 DOI: 10.1182/Blood-2016-05-714568 |
0.359 |
|
| 2016 |
Cusan M, Vegi NM, Mulaw MA, Bamezai S, Kaiser LM, Deshpande AJ, Greif PA, Quintanilla-Fend L, Göllner S, Müller-Tidow C, Humphries KR, Armstrong SA, Hiddemann W, Feuring-Buske M, Buske C. Controlled stem cell amplification by HOXB4 depends on its unique proline-rich region near the N-terminus. Blood. PMID 27827825 DOI: 10.1182/Blood-2016-04-706978 |
0.419 |
|
| 2016 |
Morgado-Palacin I, Day A, Murga M, Lafarga V, Anton ME, Tubbs A, Chen HT, Ergan A, Anderson R, Bhandoola A, Pike KG, Barlaam B, Cadogan E, Wang X, Pierce AJ, ... ... Armstrong SA, et al. Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML. Science Signaling. 9: ra91. PMID 27625305 DOI: 10.1126/Scisignal.Aad8243 |
0.4 |
|
| 2016 |
Kühn MW, Song E, Feng Z, Sinha A, Chen CW, Deshpande AJ, Cusan M, Farnoud N, Mupo A, Grove C, Koche R, Bradner JE, de Stanchina E, Vassiliou GS, Hoshii T, Armstrong SA, et al. Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia. Cancer Discovery. PMID 27535106 DOI: 10.1158/2159-8290.Cd-16-0237 |
0.469 |
|
| 2016 |
Henssen AG, Jiang E, Zhuang J, Pinello L, Socci ND, Koche R, Gonen M, Villasante CM, Armstrong SA, Bauer DE, Weng Z, Kentsis A. Forward genetic screen of human transposase genomic rearrangements. Bmc Genomics. 17: 548. PMID 27491780 DOI: 10.1186/S12864-016-2877-X |
0.304 |
|
| 2016 |
Wang K, Sanchez-Martin M, Wang X, Knapp KM, Koche R, Vu L, Nahas MK, He J, Hadler M, Stein EM, Tallman MS, Donahue AL, Frampton GM, Lipson D, Roels S, ... ... Armstrong SA, et al. Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias. Leukemia. PMID 27363283 DOI: 10.1038/Leu.2016.166 |
0.371 |
|
| 2016 |
LaFave LM, Béguelin W, Koche R, Teater M, Spitzer B, Chramiec A, Papalexi E, Keller MD, Hricik T, Konstantinoff K, Micol JB, Durham B, Knutson SK, Campbell JE, Blum G, ... ... Armstrong SA, et al. Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". Nature Medicine. 22: 578-579. PMID 27270773 DOI: 10.1038/Nm.4094 |
0.308 |
|
| 2016 |
Wang X, Chen CW, Armstrong SA. The role of DOT1L in the maintenance of leukemia gene expression. Current Opinion in Genetics & Development. 36: 68-72. PMID 27151433 DOI: 10.1016/J.Gde.2016.03.015 |
0.422 |
|
| 2016 |
Lee SC, Dvinge H, Kim E, Cho H, Micol JB, Chung YR, Durham BH, Yoshimi A, Kim YJ, Thomas M, Lobry C, Chen CW, Pastore A, Taylor J, Wang X, ... ... Armstrong SA, et al. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nature Medicine. PMID 27135740 DOI: 10.1038/Nm.4097 |
0.399 |
|
| 2016 |
Brien GL, Valerio DG, Armstrong SA. Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs. Cancer Cell. 29: 464-76. PMID 27070701 DOI: 10.1016/J.Ccell.2016.03.007 |
0.341 |
|
| 2016 |
He J, Abdel-Wahab O, Nahas MK, Wang K, Rampal RK, Intlekofer AM, Patel J, Krivstov A, Frampton GM, Young LE, Zhong S, Bailey M, White JR, Roels S, Deffenbaugh J, ... ... Armstrong SA, et al. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. Blood. PMID 26966091 DOI: 10.1182/Blood-2015-08-664649 |
0.342 |
|
| 2016 |
Riedel SS, Haladyna JN, Bezzant M, Stevens B, Pollyea DA, Sinha AU, Armstrong SA, Wei Q, Pollock RM, Daigle SR, Jordan CT, Ernst P, Neff T, Bernt KM. MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia. The Journal of Clinical Investigation. PMID 26927674 DOI: 10.1172/Jci80825 |
0.456 |
|
| 2016 |
Danis E, Yamauchi T, Echanique K, Zhang X, Haladyna JN, Riedel SS, Zhu N, Xie H, Orkin SH, Armstrong SA, Bernt KM, Neff T. Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia. Cell Reports. PMID 26904942 DOI: 10.1016/J.Celrep.2016.01.064 |
0.459 |
|
| 2016 |
Zhu N, Chen M, Eng R, DeJong J, Sinha AU, Rahnamay NF, Koche R, Al-Shahrour F, Minehart JC, Chen CW, Deshpande AJ, Xu H, Chu SH, Ebert BL, Roeder RG, ... Armstrong SA, et al. MLL-AF9- and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C. The Journal of Clinical Investigation. PMID 26878175 DOI: 10.1172/Jci82978 |
0.426 |
|
| 2016 |
Hurtz C, Chan LN, Ballabio E, Willman CL, Carroll WL, Armstrong SA, Ernst P, Melnick A, Milne T, Müschen M. Oncogenic Feedback Activation Between BCL6 and MLL Promotes Malignant Transformation in MLL-RearrangedAcute Lymphoblastic Leukemia Blood. 128: 907-907. DOI: 10.1182/Blood.V128.22.907.907 |
0.44 |
|
| 2016 |
Vu LP, Prieto C, Amin E, Minuesa G, Chhangawala S, Vidal MJ, Krivtsov AV, Chou T, Barlowe T, Taggart J, Tivnan P, Deering RP, Gonen M, Figueroa ME, Paietta E, ... ... Armstrong SA, et al. RNA Binding Protein Syncrip Regulates the Leukemia Stem Cell Program Blood. 128: 739-739. DOI: 10.1182/Blood.V128.22.739.739 |
0.466 |
|
| 2016 |
Chen CD, Delaney C, Xu H, Koche R, Lujambio Goizueta A, Hoshii T, Cusan M, Chabon J, Valerio DG, Kuehn M, Wang X, Cai S, Chu SH, Chen YK, He J, ... Armstrong SA, et al. An Epigenetic Regulator Screen Identifies Novel Targets That Sensitize MLL-Rearranged Leukemia to DOT1L Inhibition Blood. 128: 571-571. DOI: 10.1182/Blood.V128.22.571.571 |
0.462 |
|
| 2016 |
Brown FC, Still E, Cifani P, Reed C, Ficarro S, He J, Koche R, Bhola P, Romanienko P, Mark W, Krivtsov AV, Letai A, Gray N, Marto J, Armstrong SA, et al. Aberrant Phosphorylation of MEF2C Is Dispensable for Hematopoiesis, and Induces Chemotherapy Resistance and Susceptibility to MARK Kinase Inhibition Therapy in Acute Myeloid Leukemia Blood. 128: 436-436. DOI: 10.1182/Blood.V128.22.436.436 |
0.425 |
|
| 2016 |
Hoshii T, Cifani P, Nakadai T, Feng Z, Huang C, Koche R, Delaney CD, Chen CD, Lowe SW, Roeder R, Kentsis A, Armstrong SA. Non-Catalytic Role of SETD1A Regulates DNA Repair in Leukemia Blood. 128: 434-434. DOI: 10.1182/Blood.V128.22.434.434 |
0.425 |
|
| 2016 |
Chu SH, Chabon JR, Minehart J, Koche R, Li K, Witkin M, Krivtsov A, Armstrong SA. Loss of Lysine Histone Methyltransferase Setd2 Disrupts Normal Hematopoiesis, Lineage Commitment and Reveals a Novel Role for H3K36me3 in Immunoglobulin VDJ Recombination Blood. 128: 423-423. DOI: 10.1182/Blood.V128.22.423.423 |
0.407 |
|
| 2016 |
Shukla N, Wetmore C, O'Brien MM, Silverman LB, Brown P, Cooper TM, Thomson B, Blakemore SJ, Daigle S, Suttle B, Waters NJ, Krivstov AV, Armstrong SA, Ho PT, Gore L. Final Report of Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Children with Relapsed or Refractory MLL-r Acute Leukemia Blood. 128: 2780-2780. DOI: 10.1182/Blood.V128.22.2780.2780 |
0.305 |
|
| 2016 |
Kobos R, He J, Steinherz PG, Curran KJ, Renaud TM, Forlenza C, Boulad F, Prockop S, Knapp KM, Walsh M, Roshal M, Wang L, Papaemmanuil E, Dogan A, Zhong S, ... ... Armstrong SA, et al. Comprehensive Genomic Profiling for Improved Diagnosis and Therapy of Pediatric Acute Leukemias Blood. 128: 1605-1605. DOI: 10.1182/Blood.V128.22.1605.1605 |
0.375 |
|
| 2016 |
Song EJ, Chu SH, Minehart J, Chabon J, Koche R, Krivtsov A, Armstrong SA. Inhibition of MEK and DDR Pathways Induces Synergistic Killing of Novel Mll-Af4 B-ALL Model Harboring Activated Ras Mutations Blood. 128: 1511-1511. DOI: 10.1182/Blood.V128.22.1511.1511 |
0.407 |
|
| 2016 |
Toska E, Osmanbeyoglu H, Elkabets M, Chan C, Castel P, Dickler M, Armstrong S, Leslie C, Scaltriti M, José B. Abstract 885: Epigenetic regulation of estrogen receptor transcription by the PI3K pathway in breast cancer Cancer Research. 76: 885-885. DOI: 10.1158/1538-7445.Am2016-885 |
0.374 |
|
| 2016 |
Valerio DG, Xu H, Chen C, Hoshii T, Eisold M, Delaney C, Cusan M, Deshpande AJ, Huang C, Lujambio A, Zheng G, Pandita TK, Lowe SW, Armstrong SA. Abstract 2694: Histone acetyltransferase activity of MOF is required for MLL-AF9 leukemogenesis Cancer Research. 76: 2694-2694. DOI: 10.1158/1538-7445.Am2016-2694 |
0.478 |
|
| 2015 |
Cai SF, Chen CW, Armstrong SA. Drugging Chromatin in Cancer: Recent Advances and Novel Approaches. Molecular Cell. 60: 561-70. PMID 26590715 DOI: 10.1016/J.Molcel.2015.10.042 |
0.379 |
|
| 2015 |
Chen M, Zhu N, Liu X, Laurent B, Tang Z, Eng R, Shi Y, Armstrong SA, Roeder RG. JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors. Genes & Development. 29: 2123-39. PMID 26494788 DOI: 10.1101/Gad.267278.115 |
0.429 |
|
| 2015 |
Brien GL, Healy E, Jerman E, Conway E, Fadda E, O'Donovan D, Krivtsov AV, Rice AM, Kearney CJ, Flaus A, McDade SS, Martin SJ, McLysaght A, O'Connell DJ, Armstrong SA, et al. A chromatin-independent role of Polycomb-like 1 to stabilize p53 and promote cellular quiescence. Genes & Development. PMID 26494712 DOI: 10.1101/Gad.267930.115 |
0.406 |
|
| 2015 |
Chen S, Yang Z, Wilkinson AW, Deshpande AJ, Sidoli S, Krajewski K, Strahl BD, Garcia BA, Armstrong SA, Patel DJ, Gozani O. The PZP Domain of AF10 Senses Unmodified H3K27 to Regulate DOT1L-Mediated Methylation of H3K79. Molecular Cell. PMID 26439302 DOI: 10.1016/J.Molcel.2015.08.019 |
0.336 |
|
| 2015 |
LaFave LM, Béguelin W, Koche R, Teater M, Spitzer B, Chramiec A, Papalexi E, Keller MD, Hricik T, Konstantinoff K, Micol JB, Durham B, Knutson SK, Campbell JE, Blum G, ... ... Armstrong SA, et al. Loss of BAP1 function leads to EZH2-dependent transformation. Nature Medicine. PMID 26437366 DOI: 10.1038/Nm.3947 |
0.416 |
|
| 2015 |
Pelish HE, Liau BB, Nitulescu II, Tangpeerachaikul A, Poss ZC, Da Silva DH, Caruso BT, Arefolov A, Fadeyi O, Christie AL, Du K, Banka D, Schneider EV, Jestel A, Zou G, ... ... Armstrong SA, et al. Mediator kinase inhibition further activates super-enhancer-associated genes in AML. Nature. 526: 273-6. PMID 26416749 DOI: 10.1038/Nature14904 |
0.424 |
|
| 2015 |
Ye M, Zhang H, Yang H, Koche R, Staber PB, Cusan M, Levantini E, Welner RS, Bach CS, Zhang J, Krivtsov AV, Armstrong SA, Tenen DG. Hematopoietic Differentiation Is Required for Initiation of Acute Myeloid Leukemia. Cell Stem Cell. PMID 26412561 DOI: 10.1016/J.Stem.2015.08.011 |
0.448 |
|
| 2015 |
Chen CW, Armstrong SA. Targeting DOT1L and HOX Gene Expression in MLL-Rearranged Leukemia and Beyond. Experimental Hematology. PMID 26118503 DOI: 10.1016/J.Exphem.2015.05.012 |
0.455 |
|
| 2015 |
Danis E, Yamauchi T, Echanique K, Haladyna J, Kalkur R, Riedel S, Zhu N, Xie H, Bernt KM, Orkin SH, Armstrong SA, Neff T. Inactivation of Eed Impedes MLL-AF9 Mediated Leukemogenesis Through Cdkn2a-Dependent and Cdkn2a-Independent Mechanisms in a Murine Model. Experimental Hematology. PMID 26118502 DOI: 10.1016/J.Exphem.2015.06.005 |
0.45 |
|
| 2015 |
Kühn MW, Armstrong SA. Designed to kill: novel menin-MLL inhibitors target MLL-rearranged leukemia. Cancer Cell. 27: 431-3. PMID 25873167 DOI: 10.1016/J.Ccell.2015.03.012 |
0.4 |
|
| 2015 |
Chen CW, Koche RP, Sinha AU, Deshpande AJ, Zhu N, Eng R, Doench JG, Xu H, Chu SH, Qi J, Wang X, Delaney C, Bernt KM, Root DE, Hahn WC, ... ... Armstrong SA, et al. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nature Medicine. 21: 335-43. PMID 25822366 DOI: 10.1038/Nm.3832 |
0.446 |
|
| 2015 |
Stubbs MC, Kim W, Bariteau M, Davis T, Vempati S, Minehart J, Witkin M, Qi J, Krivtsov AV, Bradner JE, Kung AL, Armstrong SA. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2348-58. PMID 25688158 DOI: 10.1158/1078-0432.CCR-14-1290 |
0.386 |
|
| 2015 |
Kühn MW, Hadler MJ, Daigle SR, Koche RP, Krivtsov AV, Olhava EJ, Caligiuri MA, Huang G, Bradner JE, Pollock RM, Armstrong SA. MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition. Haematologica. 100: e190-3. PMID 25596271 DOI: 10.3324/Haematol.2014.115337 |
0.453 |
|
| 2015 |
Heidel FH, Arreba-Tutusaus P, Armstrong SA, Fischer T. Evolutionarily conserved signaling pathways: acting in the shadows of acute myelogenous leukemia's genetic diversity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 240-8. PMID 25593343 DOI: 10.1158/1078-0432.Ccr-14-1436 |
0.398 |
|
| 2015 |
Brown F, Still E, Cifani P, Ficarro S, Pouliot G, Drill E, Gonen M, He J, Balasubramanian S, Zhong S, Pavlick D, Yilmazel B, Krivtsov AV, Alonzo TA, Meshinchi S, ... ... Armstrong SA, et al. Genomic and Proteomic Analysis of Primary Chemoresistance and Induction Failure in Acute Myeloid Leukemia Blood. 126: 88-88. DOI: 10.1182/Blood.V126.23.88.88 |
0.451 |
|
| 2015 |
LaFave LM, Béguelin W, Koche R, Teater M, Papalexi E, Spitzer B, Knutson S, Campbell J, Keilhack H, Thomas PM, Kelleher NL, Abdel-Wahab O, Melnick AM, Armstrong SA, Levine RL. BAP1 Loss Results in EZH2-Dependent Transformation in Myelodysplastic Syndromes Blood. 126: 713-713. DOI: 10.1182/Blood.V126.23.713.713 |
0.438 |
|
| 2015 |
Shukla N, O'Brien MM, Silverman LB, Pauly M, Wetmore C, Loh ML, Whitlock JA, Brown P, Thomson B, Blakemore SJ, Daigle S, Pimentel P, Waters NJ, Krivstov AV, Koche R, ... Armstrong SA, et al. Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor, Pinometostat, EPZ-5676, in Children with Relapsed or Refractory MLL-r Acute Leukemia: Safety, Exposure and Target Inhibition Blood. 126: 3792-3792. DOI: 10.1182/Blood.V126.23.3792.3792 |
0.339 |
|
| 2015 |
Mar BG, Kahn J, Zon RL, Grauman PV, Boettger K, Chu SH, Armstrong SA, Ebert BL. SETD2 Heterozygous Loss in Leukemia Leads to Chemotherapy Resistance through Attenuation of the DNA Damage Response Blood. 126: 2626-2626. DOI: 10.1182/Blood.V126.23.2626.2626 |
0.381 |
|
| 2015 |
Stein EM, Garcia-Manero G, Rizzieri DA, Tibes R, Berdeja JG, Jongen-Lavrencic M, Altman JK, Dohner H, Thomson B, Blakemore SJ, Daigle S, Fine G, Waters NJ, Krivstov AV, Koche R, ... Armstrong SA, et al. A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition Blood. 126: 2547-2547. DOI: 10.1182/Blood.V126.23.2547.2547 |
0.328 |
|
| 2015 |
Riedel S, Haladyna J, Stevens B, Jordan CT, Pollyea D, Armstrong SA, Wei Q, Ernst P, Neff T, Bernt KM. Meningeoma-1 Cooperates with MLL and DOT1L to Induce Leukemia Blood. 126: 2428-2428. DOI: 10.1182/Blood.V126.23.2428.2428 |
0.445 |
|
| 2015 |
Chan LN, Chen Z, Braas D, Geng H, Hurtz C, Shojaee S, Cazzaniga V, Ng C, Ernst T, Hochhaus A, Kornblau SM, Cazzaniga G, Liu G, Milne T, Koeffler HP, ... Armstrong SA, et al. B-Lymphoid Transcription Factors Restrict Glycolytic Energy Supply for Oncogenic Signaling Blood. 126: 1255-1255. DOI: 10.1182/Blood.V126.23.1255.1255 |
0.37 |
|
| 2015 |
Smitheman K, Cusan M, Liu Y, Butticello M, Pappalardi M, Foley J, Federowicz K, Aller GV, Kasparec J, Tian X, Suarez D, Schneck J, Carson J, McDevitt P, Ho T, ... Armstrong S, et al. Abstract 3513: Inhibition of LSD1 for the treatment of cancer Cancer Research. 75: 3513-3513. DOI: 10.1158/1538-7445.Am2015-3513 |
0.462 |
|
| 2015 |
Mohr J, Frey S, Bullinger L, Schnoeder TM, Weinert S, Huber TB, Kaehne T, Armstrong SA, Fischer T, Heidel FH. Distinct and non-overlapping functions of Llgl1 and scribble in hematopoietic stem cells Experimental Hematology. 43: S67. DOI: 10.1016/J.Exphem.2015.06.140 |
0.343 |
|
| 2014 |
Cowley GS, Weir BA, Vazquez F, Tamayo P, Scott JA, Rusin S, East-Seletsky A, Ali LD, Gerath WF, Pantel SE, Lizotte PH, Jiang G, Hsiao J, Tsherniak A, Dwinell E, ... ... Armstrong SA, et al. Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Scientific Data. 1: 140035. PMID 25984343 DOI: 10.1038/Sdata.2014.35 |
0.376 |
|
| 2014 |
Rampal R, Ahn J, Abdel-Wahab O, Nahas M, Wang K, Lipson D, Otto GA, Yelensky R, Hricik T, McKenney AS, Chiosis G, Chung YR, Pandey S, van den Brink MR, Armstrong SA, et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proceedings of the National Academy of Sciences of the United States of America. 111: E5401-10. PMID 25516983 DOI: 10.1073/Pnas.1407792111 |
0.419 |
|
| 2014 |
Bruedigam C, Bagger FO, Heidel FH, Paine Kuhn C, Guignes S, Song A, Austin R, Vu T, Lee E, Riyat S, Moore AS, Lock RB, Bullinger L, Hill GR, Armstrong SA, et al. Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy. Cell Stem Cell. 15: 775-90. PMID 25479751 DOI: 10.1016/J.Stem.2014.11.010 |
0.464 |
|
| 2014 |
Deshpande AJ, Deshpande A, Sinha AU, Chen L, Chang J, Cihan A, Fazio M, Chen CW, Zhu N, Koche R, Dzhekieva L, Ibáñez G, Dias S, Banka D, Krivtsov A, ... ... Armstrong SA, et al. AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes. Cancer Cell. 26: 896-908. PMID 25464900 DOI: 10.1016/J.Ccell.2014.10.009 |
0.438 |
|
| 2014 |
Huang CH, Lujambio A, Zuber J, Tschaharganeh DF, Doran MG, Evans MJ, Kitzing T, Zhu N, de Stanchina E, Sawyers CL, Armstrong SA, Lewis JS, Sherr CJ, Lowe SW. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes & Development. 28: 1800-14. PMID 25128497 DOI: 10.1101/Gad.244368.114 |
0.31 |
|
| 2014 |
Santos MA, Faryabi RB, Ergen AV, Day AM, Malhowski A, Canela A, Onozawa M, Lee JE, Callen E, Gutierrez-Martinez P, Chen HT, Wong N, Finkel N, Deshpande A, Sharrow S, ... ... Armstrong SA, et al. DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier. Nature. 514: 107-11. PMID 25079327 DOI: 10.1038/Nature13483 |
0.444 |
|
| 2014 |
Hanoun M, Zhang D, Mizoguchi T, Pinho S, Pierce H, Kunisaki Y, Lacombe J, Armstrong SA, Dührsen U, Frenette PS. Acute myelogenous leukemia-induced sympathetic neuropathy promotes malignancy in an altered hematopoietic stem cell niche. Cell Stem Cell. 15: 365-75. PMID 25017722 DOI: 10.1016/J.Stem.2014.06.020 |
0.398 |
|
| 2014 |
Placke T, Faber K, Nonami A, Putwain SL, Salih HR, Heidel FH, Krämer A, Root DE, Barbie DA, Krivtsov AV, Armstrong SA, Hahn WC, Huntly BJ, Sykes SM, Milsom MD, et al. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood. 124: 13-23. PMID 24764564 DOI: 10.1182/Blood-2014-02-558114 |
0.499 |
|
| 2014 |
Koche RP, Armstrong SA. Genomic dark matter sheds light on EVI1-driven leukemia. Cancer Cell. 25: 407-8. PMID 24735919 DOI: 10.1016/J.Ccr.2014.03.031 |
0.353 |
|
| 2014 |
Mar BG, Bullinger LB, McLean KM, Grauman PV, Harris MH, Stevenson K, Neuberg DS, Sinha AU, Sallan SE, Silverman LB, Kung AL, Lo Nigro L, Ebert BL, Armstrong SA. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nature Communications. 5: 3469. PMID 24662245 DOI: 10.1038/Ncomms4469 |
0.361 |
|
| 2014 |
Wee S, Dhanak D, Li H, Armstrong SA, Copeland RA, Sims R, Baylin SB, Liu XS, Schweizer L. Targeting epigenetic regulators for cancer therapy. Annals of the New York Academy of Sciences. 1309: 30-6. PMID 24571255 DOI: 10.1111/Nyas.12356 |
0.424 |
|
| 2014 |
Ng CE, Sinha A, Krivtsov A, Dias S, Chang J, Armstrong SA, Kalaitzidis D. KRas(G12D)-evoked leukemogenesis does not require β-catenin. Leukemia. 28: 698-702. PMID 24189294 DOI: 10.1038/Leu.2013.328 |
0.36 |
|
| 2014 |
Riedel S, Bernt KM, Haladyna J, Bezzant M, Stevens B, Pollyea DA, Sinha AU, Armstrong SA, Wei Q, Jordan CT, Neff T. Targeting Meningeoma-1 Driven AML through Epigenetic Modulation of the Cell of Origin Blood. 124: 838-838. DOI: 10.1182/Blood.V124.21.838.838 |
0.47 |
|
| 2014 |
Danis E, Yamauchi T, Echanique K, Haladyna J, Xie H, Zhu N, Riedel S, Bernt KM, Orkin SH, Armstrong SA, Neff T. Context Dependent Role of Polycomb Repressive Complex 2 in Acute Leukemia Blood. 124: 610-610. DOI: 10.1182/Blood.V124.21.610.610 |
0.5 |
|
| 2014 |
Yi JS, Federation A, Qi J, Dhe-Paganon S, Hadler M, Xu X, Varca A, St. Pierre R, Armstrong SA, Bradner JE. Structure-Guided Design of DOT1L Methyltransferase Inhibitors By a Novel, Label Free Assay Platform Blood. 124: 4811-4811. DOI: 10.1182/Blood.V124.21.4811.4811 |
0.392 |
|
| 2014 |
Xu H, Deblassio TR, Armstrong SA, Nimer S. Role of p21 in a Mouse Model of NUP98-HOXD13 Fusion Driven Myelodysplastic Syndromes (MDS) Blood. 124: 4616-4616. DOI: 10.1182/Blood.V124.21.4616.4616 |
0.363 |
|
| 2014 |
Stein EM, Garcia-Manero G, Rizzieri DA, Savona M, Tibes R, Altman JK, Jongen-Lavrencic M, Döhner H, Armstrong S, Pollock RM, Waters NJ, Legler M, Thomson B, Daigle S, McDonald A, et al. The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia Blood. 124: 387-387. DOI: 10.1182/Blood.V124.21.387.387 |
0.337 |
|
| 2014 |
Krivtsov AV, Wang X, Farnoud NR, Hadler M, Martin MS, Knapp KM, Stein EM, Lipson D, Nahas MK, Stephens PJ, Sanford EM, Wang K, Frampton GM, Brennan T, Otto GA, ... ... Armstrong SA, et al. Patient Derived Xenograft (PDX) Models Recapitulate the Genomic-Driver Composition of Acute Leukemia Samples Blood. 124: 286-286. DOI: 10.1182/Blood.V124.21.286.286 |
0.323 |
|
| 2014 |
He J, Bufill JA, Nahas MK, Wang K, Young LE, Knapp KM, Brennan KW, Donahue AL, Young G, Ross JS, Morosini D, van den Brink MRM, Abdel-Wahab O, Rampal RK, Intlekofer AM, ... ... Armstrong S, et al. Clinical Utility of Comprehensive Profiling of Genomic Alterations in Hematologic Malignancies Blood. 124: 1072-1072. DOI: 10.1182/Blood.V124.21.1072.1072 |
0.372 |
|
| 2014 |
Coombs CC, Viny AD, He J, Kobos R, Lipson D, Shukla N, Knapp KM, Otto G, Abdel-Wahab O, Stein EM, Rampal RK, Miller VA, Dogan A, van den Brink MR, Armstrong SA, et al. Utility of Combined DNA and RNA Next Generation Sequencing in Leukemias for Identification of Prognostic and Therapeutically Relevant Genomic Alterations in Clinical Practice Blood. 124: 1039-1039. DOI: 10.1182/Blood.V124.21.1039.1039 |
0.356 |
|
| 2014 |
Armstrong SA. Abstract IA22: Targeting histone modifying enzymes in leukemia Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-Ia22 |
0.42 |
|
| 2014 |
Deshpande A, Deshpande A, Sinha A, Chen L, Chang J, Chen D, Koche R, Krivtsov A, Luo M, Bradner J, Bernt K, Armstrong S. Regulation of HOX gene expression by AF10-mediated conversion of H3K79me1 to H3K79me2 Experimental Hematology. 42: S30. DOI: 10.1016/J.Exphem.2014.07.107 |
0.36 |
|
| 2014 |
Armstrong S. Chasing leukemia stem cells Experimental Hematology. 42: S7. DOI: 10.1016/J.Exphem.2014.07.022 |
0.365 |
|
| 2013 |
Chu SH, Armstrong SA. Stem cells: Dual response to Ras mutation. Nature. 504: 91-2. PMID 24284623 DOI: 10.1038/Nature12840 |
0.372 |
|
| 2013 |
Altschuler GM, Hofmann O, Kalatskaya I, Payne R, Ho Sui SJ, Saxena U, Krivtsov AV, Armstrong SA, Cai T, Stein L, Hide WA. Pathprinting: An integrative approach to understand the functional basis of disease. Genome Medicine. 5: 68. PMID 23890051 DOI: 10.1186/Gm472 |
0.362 |
|
| 2013 |
Miller PG, Al-Shahrour F, Hartwell KA, Chu LP, Järås M, Puram RV, Puissant A, Callahan KP, Ashton J, McConkey ME, Poveromo LP, Cowley GS, Kharas MG, Labelle M, Shterental S, ... ... Armstrong SA, et al. In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. Cancer Cell. 24: 45-58. PMID 23770013 DOI: 10.1016/J.Ccr.2013.05.004 |
0.452 |
|
| 2013 |
Neff T, Armstrong SA. Recent progress toward epigenetic therapies: the example of mixed lineage leukemia. Blood. 121: 4847-53. PMID 23649466 DOI: 10.1182/Blood-2013-02-474833 |
0.418 |
|
| 2013 |
Mullally A, Bruedigam C, Poveromo L, Heidel FH, Purdon A, Vu T, Austin R, Heckl D, Breyfogle LJ, Kuhn CP, Kalaitzidis D, Armstrong SA, Williams DA, Hill GR, Ebert BL, et al. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera. Blood. 121: 3692-702. PMID 23487027 DOI: 10.1182/Blood-2012-05-432989 |
0.412 |
|
| 2013 |
Ho LL, Sinha A, Verzi M, Bernt KM, Armstrong SA, Shivdasani RA. DOT1L-mediated H3K79 methylation in chromatin is dispensable for Wnt pathway-specific and other intestinal epithelial functions. Molecular and Cellular Biology. 33: 1735-45. PMID 23428873 DOI: 10.1128/Mcb.01463-12 |
0.43 |
|
| 2013 |
Deshpande AJ, Chen L, Fazio M, Sinha AU, Bernt KM, Banka D, Dias S, Chang J, Olhava EJ, Daigle SR, Richon VM, Pollock RM, Armstrong SA. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood. 121: 2533-41. PMID 23361907 DOI: 10.1182/Blood-2012-11-465120 |
0.422 |
|
| 2013 |
Lobry C, Ntziachristos P, Ndiaye-Lobry D, Oh P, Cimmino L, Zhu N, Araldi E, Hu W, Freund J, Abdel-Wahab O, Ibrahim S, Skokos D, Armstrong SA, Levine RL, Park CY, et al. Notch pathway activation targets AML-initiating cell homeostasis and differentiation. The Journal of Experimental Medicine. 210: 301-19. PMID 23359070 DOI: 10.1084/Jem.20121484 |
0.381 |
|
| 2013 |
Heidel FH, Bullinger L, Arreba-Tutusaus P, Wang Z, Gaebel J, Hirt C, Niederwieser D, Lane SW, Döhner K, Vasioukhin V, Fischer T, Armstrong SA. The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML Journal of Experimental Medicine. 210: 15-22. PMID 23277453 DOI: 10.1084/Jem.20120596 |
0.436 |
|
| 2013 |
Krivtsov AV, Figueroa ME, Sinha AU, Stubbs MC, Feng Z, Valk PJM, Delwel R, Döhner K, Bullinger L, Kung AL, Melnick AM, Armstrong SA. Cell of origin determines clinically relevant subtypes of MLL-rearranged AML Leukemia. 27: 852-860. PMID 23235717 DOI: 10.1038/Leu.2012.363 |
0.485 |
|
| 2013 |
Chen L, Deshpande AJ, Banka D, Bernt KM, Dias S, Buske C, Olhava EJ, Daigle SR, Richon VM, Pollock RM, Armstrong SA. Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia. 27: 813-22. PMID 23138183 DOI: 10.1038/leu.2012.327 |
0.391 |
|
| 2013 |
Hurtz C, Geng H, Ballabio E, Xiao G, Ng C, Masouleh BK, Willman CL, Armstrong SA, Milne T, Melnick A, Muschen M. Identification Of BCL6 As a Therapeutic Target In MLL-Rearranged ALL Blood. 122: 72-72. DOI: 10.1182/Blood.V122.21.72.72 |
0.451 |
|
| 2013 |
David Chen C, Sinha AU, Qi J, Deshpande AJ, Zhu N, Koche R, Eng R, Chang J, Hahn WC, Bradner JE, Armstrong SA. Genome-Wide RNAi Screen Identifies The Mechanistic Role For DOT1L In MLL-Rearranged Leukemia Blood. 122: 598-598. DOI: 10.1182/Blood.V122.21.598.598 |
0.476 |
|
| 2013 |
Kruger RG, Mohammad H, Smitheman K, Cusan M, Liu Y, Pappalardi M, Federowicz K, Van Aller G, Kasparec J, Tian X, Suarez D, Rouse M, Schneck J, Carson J, McDevitt P, ... Armstrong SA, et al. Inhibition Of LSD1 As a Therapeutic Strategy For The Treatment Of Acute Myeloid Leukemia Blood. 122: 3964-3964. DOI: 10.1182/Blood.V122.21.3964.3964 |
0.483 |
|
| 2013 |
Hanoun M, Zhang D, Pinho S, Mizoguchi T, Lacombe J, Armstrong SA, Duehrsen U, Frenette PS. Acute Myeloid Leukemia Alters The Mesenchymal Stem Cell Potential Of The HSC Niche: Evidence For Modulation By β-Adrenergic Signals Blood. 122: 342-342. DOI: 10.1182/Blood.V122.21.342.342 |
0.448 |
|
| 2013 |
Bruedigam C, Bagger FO, Kuhn CP, Vu T, Austin R, Heidel FH, Bullinger L, Hill GR, Armstrong SA, Williams DA, Lane SW. Inhibition Of Telomerase Is a Novel and Effective Therapy In MLL-Rearranged Acute Myeloid Leukemia (AML) Blood. 122: 2887-2887. DOI: 10.1182/Blood.V122.21.2887.2887 |
0.435 |
|
| 2013 |
Deshpande AJ, Chen L, Sinha AU, Zhu N, Chen D, Chang J, Krivtsov AV, Bernt K, Bradner JE, Armstrong SA. Regulation Of Normal and Malignant Hoxa Gene Expression Through Higher H3K79 Methylated States Blood. 122: 2492-2492. DOI: 10.1182/Blood.V122.21.2492.2492 |
0.43 |
|
| 2013 |
Lipson D, Nahas MK, Otto GA, Yelensky R, Abdel-Wahab O, Wang K, He J, Intlekofer AM, Rampal RK, Brennan TA, Knapp KM, Brennan KW, Young G, Donahue AL, Sanford EM, ... ... Armstrong SA, et al. Identification Of Actionable Genomic Alterations In Hematologic Malignancies By a Clinical Next Generation Sequencing-Based Assay Blood. 122: 230-230. DOI: 10.1182/Blood.V122.21.230.230 |
0.376 |
|
| 2013 |
Krivtsov AV, Xujun W, Farnoud NR, Hadler M, Knapp KM, Stein EM, Tallman MS, Donahue AL, Lipson D, Nahas MK, Stephens PJ, Sanford EM, Wang K, Frampton GM, Brennan T, ... ... Armstrong SA, et al. Patient Derived Xenograft (PDX) Models Faithfully Recapitulate The Genetic Composition Of Primary AML Blood. 122: 1328-1328. DOI: 10.1182/Blood.V122.21.1328.1328 |
0.321 |
|
| 2013 |
Kühn MW, Hadler M, Daigle SR, Chen C, Sinha AU, Krivtsov AV, Olhava EJ, Caligiuri MA, Bradner JE, Pollock RM, Armstrong SA. Myeloid Leukemia Cells With MLL partial Tandem Duplication Are Sensitive To Pharmacological Inhibition Of The H3K79 Methyltransferase DOT1L Blood. 122: 1256-1256. DOI: 10.1182/Blood.V122.21.1256.1256 |
0.489 |
|
| 2013 |
Armstrong SA. Abstract IA08: Targeting histone methylation in leukemia Cancer Research. 73. DOI: 10.1158/1538-7445.Cec13-Ia08 |
0.476 |
|
| 2012 |
Krivtsov AV, Armstrong SA. Cancer. Can one cell influence cancer heterogeneity? Science (New York, N.Y.). 338: 1035-6. PMID 23180850 DOI: 10.1126/Science.1231594 |
0.352 |
|
| 2012 |
Kalaitzidis D, Sykes SM, Wang Z, Punt N, Tang Y, Ragu C, Sinha AU, Lane SW, Souza AL, Clish CB, Anastasiou D, Gilliland DG, Scadden DT, Guertin DA, Armstrong SA. mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. Cell Stem Cell. 11: 429-39. PMID 22958934 DOI: 10.1016/j.stem.2012.06.009 |
0.381 |
|
| 2012 |
Deshpande AJ, Bradner J, Armstrong SA. Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. Trends in Immunology. 33: 563-70. PMID 22867873 DOI: 10.1016/J.It.2012.06.002 |
0.399 |
|
| 2012 |
Bindels EM, Havermans M, Lugthart S, Erpelinck C, Wocjtowicz E, Krivtsov AV, Rombouts E, Armstrong SA, Taskesen E, Haanstra JR, Beverloo HB, Döhner H, Hudson WA, Kersey JH, Delwel R, et al. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs. Blood. 119: 5838-49. PMID 22553314 DOI: 10.1182/Blood-2011-11-393827 |
0.407 |
|
| 2012 |
Heidel FH, Bullinger L, Feng Z, Wang Z, Neff TA, Stein L, Kalaitzidis D, Lane SW, Armstrong SA. Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell. 10: 412-24. PMID 22482506 DOI: 10.1016/J.Stem.2012.02.017 |
0.334 |
|
| 2012 |
Neff T, Sinha AU, Kluk MJ, Zhu N, Khattab MH, Stein L, Xie H, Orkin SH, Armstrong SA. Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proceedings of the National Academy of Sciences of the United States of America. 109: 5028-33. PMID 22396593 DOI: 10.1073/Pnas.1202258109 |
0.47 |
|
| 2012 |
Onder TT, Kara N, Cherry A, Sinha AU, Zhu N, Bernt KM, Cahan P, Marcarci BO, Unternaehrer J, Gupta PB, Lander ES, Armstrong SA, Daley GQ. Chromatin-modifying enzymes as modulators of reprogramming. Nature. 483: 598-602. PMID 22388813 DOI: 10.1038/Nature10953 |
0.417 |
|
| 2012 |
Mar BG, Bullinger L, Basu E, Schlis K, Silverman LB, Döhner K, Armstrong SA. Sequencing histone-modifying enzymes identifies UTX mutations in acute lymphoblastic leukemia Leukemia. 26: 1881-1883. PMID 22377896 DOI: 10.1038/Leu.2012.56 |
0.316 |
|
| 2012 |
Trowbridge JJ, Sinha AU, Zhu N, Li M, Armstrong SA, Orkin SH. Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains. Genes & Development. 26: 344-9. PMID 22345515 DOI: 10.1101/gad.184341.111 |
0.42 |
|
| 2012 |
Ho Sui SJ, Begley K, Reilly D, Chapman B, McGovern R, Rocca-Sera P, Maguire E, Altschuler GM, Hansen TA, Sompallae R, Krivtsov A, Shivdasani RA, Armstrong SA, Culhane AC, Correll M, et al. The Stem Cell Discovery Engine: an integrated repository and analysis system for cancer stem cell comparisons. Nucleic Acids Research. 40: D984-91. PMID 22121217 DOI: 10.1093/Nar/Gkr1051 |
0.386 |
|
| 2012 |
Hurtz C, Ramezani-Rad P, Geng H, Kharabi B, Carroll WL, Willman CL, Armstrong SA, Melnick A, Muschen M. Targeting BCL6-Mediated Drug-Resistance in High-Risk Childhood ALL Blood. 120: 776-776. DOI: 10.1182/Blood.V120.21.776.776 |
0.443 |
|
| 2012 |
Deshpande AJ, Chen L, Bernt KM, Dias S, Banka D, Sinha AU, Chen D, Punt N, Bradner JE, Armstrong SA. The Interaction Between DOT1L and AF10 Is Required for H3K79 Dimethylation and MLL-AF9 Leukemia Blood. 120: 401-401. DOI: 10.1182/Blood.V120.21.401.401 |
0.445 |
|
| 2012 |
Deshpande AJ, Chen L, Fazio M, Sinha AU, Bernt KM, Banka D, Dias S, Olhava EJ, Daigle SR, Richon VM, Pollock RM, Armstrong SA. MLL-AF6 Mediated Transformation Is Dependent On the H3K79 Methyl-transferase Dot1l Blood. 120: 3502-3502. DOI: 10.1182/Blood.V120.21.3502.3502 |
0.462 |
|
| 2012 |
Heidel FH, Bullinger L, Wang Z, Arreba-Tutusaus P, Hirt C, Niederwieser D, Dohner K, Fischer T, Armstrong SA. Inactivation of the Cell Fate Determinate Llgl1 (Lethal Giant Larvae Homolog 1) Leads to Enhanced HSC Fitness and Predicts a Poor Prognosis in AML. Blood. 120: 2293-2293. DOI: 10.1182/Blood.V120.21.2293.2293 |
0.467 |
|
| 2012 |
Yusuf RZ, Acharya SS, Yu VW, Saez B, Cobert JM, Doench J, Bullinger L, S'aulis D, Lee D, Palchaudhuri R, Uzosike AC, Duvet M, Logan DJ, Das S, Cook CM, ... ... Armstrong SA, et al. Aldehyde Dehydrogenase 3a2 (Aldh3a2) Represents a Distinct Metabolic Vulnerability in MLL-AF9 AML Leukemia Initiating Cells Blood. 120: 208-208. DOI: 10.1182/Blood.V120.21.208.208 |
0.434 |
|
| 2012 |
Armstrong SA. Abstract SY35-03: Gene expression and epigenetic programs in leukemia stem cell development Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Sy35-03 |
0.478 |
|
| 2011 |
Bernt KM, Armstrong SA. Targeting epigenetic programs in MLL-rearranged leukemias. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2011: 354-60. PMID 22160057 DOI: 10.1182/Asheducation-2011.1.354 |
0.43 |
|
| 2011 |
Bernt KM, Armstrong SA. A role for DOT1L in MLL-rearranged leukemias. Epigenomics. 3: 667-70. PMID 22126283 DOI: 10.2217/Epi.11.98 |
0.427 |
|
| 2011 |
Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B, Ferraro F, Mercier F, Singh H, Brumme KM, Acharya SS, Scholl C, Schöll C, Tothova Z, Attar EC, ... ... Armstrong SA, et al. AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell. 146: 697-708. PMID 21884932 DOI: 10.1016/J.Cell.2011.07.032 |
0.421 |
|
| 2011 |
Heidel FH, Mar BG, Armstrong SA. Self-renewal related signaling in myeloid leukemia stem cells. International Journal of Hematology. 94: 109-17. PMID 21800073 DOI: 10.1007/S12185-011-0901-0 |
0.361 |
|
| 2011 |
Lane SW, Wang YJ, Lo Celso C, Ragu C, Bullinger L, Sykes SM, Ferraro F, Shterental S, Lin CP, Gilliland DG, Scadden DT, Armstrong SA, Williams DA. Differential niche and Wnt requirements during acute myeloid leukemia progression Blood. 118: 2849-2856. PMID 21765021 DOI: 10.1182/Blood-2011-03-345165 |
0.42 |
|
| 2011 |
Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, Feng Z, Punt N, Daigle A, Bullinger L, Pollock RM, Richon VM, Kung AL, Armstrong SA. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell. 20: 66-78. PMID 21741597 DOI: 10.1016/J.Ccr.2011.06.010 |
0.467 |
|
| 2011 |
Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, Johnston LD, Scott MP, Smith JJ, Xiao Y, Jin L, Kuntz KW, Chesworth R, Moyer MP, Bernt KM, ... ... Armstrong SA, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 20: 53-65. PMID 21741596 DOI: 10.1016/j.ccr.2011.06.009 |
0.435 |
|
| 2011 |
Deshpande AJ, Rouhi A, Lin Y, Stadler C, Greif PA, Arseni N, Opatz S, Quintanilla-Fend L, Holzmann K, Hiddemann W, Döhner K, Döhner H, Xu G, Armstrong SA, Bohlander SK, et al. The clathrin-binding domain of CALM and the OM-LZ domain of AF10 are sufficient to induce acute myeloid leukemia in mice. Leukemia. 25: 1718-27. PMID 21681188 DOI: 10.1038/Leu.2011.153 |
0.331 |
|
| 2011 |
Kalaitzidis D, Armstrong SA. Cancer: The flipside of Notch. Nature. 473: 159-60. PMID 21562551 DOI: 10.1038/473159A |
0.382 |
|
| 2011 |
Zimmer SN, Zhou Q, Zhou T, Cheng Z, Abboud-Werner SL, Horn D, Lecocke M, White R, Krivtsov AV, Armstrong SA, Kung AL, Livingston DM, Rebel VI. Crebbp haploinsufficiency in mice alters the bone marrow microenvironment, leading to loss of stem cells and excessive myelopoiesis. Blood. 118: 69-79. PMID 21555743 DOI: 10.1182/Blood-2010-09-307942 |
0.386 |
|
| 2011 |
Kvinlaug BT, Chan WI, Bullinger L, Ramaswami M, Sears C, Foster D, Lazic SE, Okabe R, Benner A, Lee BH, De Silva I, Valk PJ, Delwel R, Armstrong SA, Döhner H, et al. Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias. Cancer Research. 71: 4117-29. PMID 21505102 DOI: 10.1158/0008-5472.Can-11-0176 |
0.401 |
|
| 2011 |
Yusuf RZ, Acharya SS, Yu V, Saez B, Duvet M, Scadden E, Warraich G, Clish C, Churchill M, Doench J, Logan DJ, Cook C, Das S, Brown A, Sykes SM, ... ... Armstrong SA, et al. Distinct Metabolic Dependency of Normal and Leukemic Cells in a Mouse Model Blood. 118: 759-759. DOI: 10.1182/Blood.V118.21.759.759 |
0.412 |
|
| 2011 |
High LM, Papa RA, Armstrong SA, Lock RB. Abstract LB-23: In vivo exposure of infant leukemia to the BH3-mimetic ABT-263 selects for a cell death-resistant phenotype Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-23 |
0.372 |
|
| 2011 |
Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B, Ferraro F, Mercier F, Singh H, Brumme KM, Acharya SS, Scholl C, Tothova Z, Attar EC, Fröhling S, ... ... Armstrong SA, et al. Erratum: AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias (Cell (2011) 146 (697-708)) Cell. 147. DOI: 10.1016/J.Cell.2011.09.015 |
0.369 |
|
| 2010 |
Shannon K, Armstrong SA. Genetics, epigenetics, and leukemia. The New England Journal of Medicine. 363: 2460-1. PMID 21067376 DOI: 10.1056/Nejme1012071 |
0.394 |
|
| 2010 |
Claus R, Plass C, Armstrong SA, Bullinger L. DNA methylation profiling in acute myeloid leukemia: from recent technological advances to biological and clinical insights. Future Oncology (London, England). 6: 1415-31. PMID 20919827 DOI: 10.2217/Fon.10.110 |
0.358 |
|
| 2010 |
Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z, Zon LI, Armstrong SA. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science (New York, N.Y.). 327: 1650-3. PMID 20339075 DOI: 10.1126/Science.1186624 |
0.344 |
|
| 2010 |
Juszczynski P, Rodig SJ, Ouyang J, O'Donnell E, Takeyama K, Mlynarski W, Mycko K, Szczepanski T, Gaworczyk A, Krivtsov A, Faber J, Sinha AU, Rabinovich GA, Armstrong SA, Kutok JL, et al. MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 2122-30. PMID 20332322 DOI: 10.1158/1078-0432.Ccr-09-2765 |
0.383 |
|
| 2010 |
Cairo MS, Jordan CT, Maley CC, Chao C, Melnick A, Armstrong SA, Shlomchik W, Molldrem J, Ferrone S, Mackall C, Zitvogel L, Bishop MR, Giralt SA, June CH. NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 16: 709-28. PMID 20227509 DOI: 10.1016/J.Bbmt.2010.03.002 |
0.368 |
|
| 2010 |
Bullinger L, Armstrong SA. HELP for AML: Methylation Profiling Opens New Avenues Cancer Cell. 17: 1-3. PMID 20129241 DOI: 10.1016/J.Ccr.2009.12.033 |
0.339 |
|
| 2010 |
Stam RW, Den Boer ML, Schneider P, de Boer J, Hagelstein J, Valsecchi MG, de Lorenzo P, Sallan SE, Brady HJ, Armstrong SA, Pieters R. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia. Blood. 115: 1018-25. PMID 19965632 DOI: 10.1182/Blood-2009-02-205963 |
0.343 |
|
| 2010 |
Jeong J, Krivtsov A, Armstrong S, Hide W. Pathway guided modules − Searching for causality in expression data in cancer cells F1000research. 1. DOI: 10.7490/F1000Research.411.1 |
0.319 |
|
| 2010 |
Begley K, Reilly D, McGovern R, Zhang W, Altschuler G, Jeong J, Sompallae R, Krivtsov A, Sinha A, Armstrong S, Hofmann O, Hide W. Development of the Stem Cell Discovery Engine (SCDE) F1000research. 1. DOI: 10.7490/F1000Research.308.1 |
0.311 |
|
| 2010 |
Heidel FH, Neff TA, Feng Z, Armstrong SA. β-Catenin Suppression Targets Imatinib Resistant Leukemia Stem Cells In Mice with BCR-ABL Induced Myeloproliferative Disease Blood. 116: 93-93. DOI: 10.1182/Blood.V116.21.93.93 |
0.416 |
|
| 2010 |
Neff TA, Heidel FH, Armstrong S. Bmi-1 Is Dispensable for the Development of Acute Myeloid Leukemia Mediated by MLL-AF9 Blood. 116: 63-63. DOI: 10.1182/Blood.V116.21.63.63 |
0.38 |
|
| 2010 |
Bernt KM, Zhu N, Faber J, Punt N, Pollock RM, Richon VM, Kung AL, Armstrong S. Demonstration of a Role for Dot1l In MLL-Rearranged Leukemia Using a Conditional Loss of Function Model Blood. 116: 62-62. DOI: 10.1182/Blood.V116.21.62.62 |
0.5 |
|
| 2010 |
Schlis KD, Stubbs M, DeAngelo DJ, Neuberg D, Dahlberg SE, Sallan SE, Armstrong SA, Silverman LB. A Pilot Trial of Rapamycin with Glucocorticoids In Children and Adults with Relapsed ALL Blood. 116: 3244-3244. DOI: 10.1182/Blood.V116.21.3244.3244 |
0.33 |
|
| 2009 |
Krivtsov AV, Feng Z, Armstrong SA. Transformation from committed progenitor to leukemia stem cells. Annals of the New York Academy of Sciences. 1176: 144-9. PMID 19796242 DOI: 10.1111/J.1749-6632.2009.04966.X |
0.421 |
|
| 2009 |
Hofmann I, Stover EH, Cullen DE, Mao J, Morgan KJ, Lee BH, Kharas MG, Miller PG, Cornejo MG, Okabe R, Armstrong SA, Ghilardi N, Gould S, de Sauvage FJ, McMahon AP, et al. Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis. Cell Stem Cell. 4: 559-67. PMID 19497284 DOI: 10.1016/J.Stem.2009.03.016 |
0.39 |
|
| 2009 |
Neff T, Armstrong SA. Chromatin maps, histone modifications and leukemia. Leukemia. 23: 1243-51. PMID 19322211 DOI: 10.1038/Leu.2009.40 |
0.388 |
|
| 2009 |
Krivtsov AV, Wang Y, Feng Z, Armstrong SA. Gene expression profiling of leukemia stem cells. Methods in Molecular Biology (Clifton, N.J.). 538: 231-46. PMID 19277590 DOI: 10.1007/978-1-59745-418-6_11 |
0.424 |
|
| 2009 |
Gekas C, Rhodes KE, Gereige LM, Helgadottir H, Ferrari R, Kurdistani SK, Montecino-Rodriguez E, Bassel-Duby R, Olson E, Krivtsov AV, Armstrong S, Orkin SH, Pellegrini M, Mikkola HK. Mef2C is a lineage-restricted target of Scl/Tal1 and regulates megakaryopoiesis and B-cell homeostasis. Blood. 113: 3461-71. PMID 19211936 DOI: 10.1182/Blood-2008-07-167577 |
0.426 |
|
| 2009 |
Bernt KM, Armstrong SA. Leukemia stem cells and human acute lymphoblastic leukemia. Seminars in Hematology. 46: 33-8. PMID 19100366 DOI: 10.1053/J.Seminhematol.2008.09.010 |
0.416 |
|
| 2009 |
Faber J, Krivtsov AV, Stubbs MC, Wright R, Davis TN, van den Heuvel-Eibrink M, Zwaan CM, Kung AL, Armstrong SA. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood. 113: 2375-85. PMID 19056693 DOI: 10.1182/Blood-2007-09-113597 |
0.492 |
|
| 2009 |
Wang Y, Krivtsov AV, Sinha AU, North T, Goessling W, Zon LI, Armstrong S. β-Catenin Determines Developmental Stage Specific Transformation by Hox Genes. Blood. 114: 385-385. DOI: 10.1182/Blood.V114.22.385.385 |
0.358 |
|
| 2009 |
Krivtsov AV, Sinha AU, Stubbs MC, Kung A, Armstrong S. Cell of Origin Influences Leukemia Stem Cell Phenotype. Blood. 114: 3459-3459. DOI: 10.1182/Blood.V114.22.3459.3459 |
0.449 |
|
| 2009 |
Bernt K, Faber J, Davis TN, Kung A, Armstrong S. DOT1L and Histone H3 Lysine79 Methylation as a Therapeutic Target in Mixed Lineage Leukemia. Blood. 114: 212-212. DOI: 10.1182/Blood.V114.22.212.212 |
0.481 |
|
| 2008 |
Jones RJ, Armstrong SA. Cancer Stem Cells in Hematopoietic Malignancies. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 14: 12-16. PMID 19122742 DOI: 10.1016/J.Bbmt.2007.10.012 |
0.387 |
|
| 2008 |
Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU, Xia X, Jesneck J, Bracken AP, Silverman LB, Kutok JL, Kung AL, Armstrong SA. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell. 14: 355-68. PMID 18977325 DOI: 10.1016/J.Ccr.2008.10.001 |
0.428 |
|
| 2008 |
Faber J, Gregory RI, Armstrong SA. Linking miRNA regulation to BCR-ABL expression: the next dimension. Cancer Cell. 13: 467-9. PMID 18538729 DOI: 10.1016/J.Ccr.2008.05.013 |
0.355 |
|
| 2008 |
Wang Y, Armstrong SA. Cancer: inappropriate expression of stem cell programs? Cell Stem Cell. 2: 297-9. PMID 18397746 DOI: 10.1016/J.Stem.2008.03.014 |
0.388 |
|
| 2008 |
Del Gaizo Moore V, Schlis KD, Sallan SE, Armstrong SA, Letai A. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood. 111: 2300-9. PMID 18056841 DOI: 10.1182/Blood-2007-06-098012 |
0.381 |
|
| 2008 |
Stubbs MC, Kim YM, Krivtsov AV, Wright RD, Feng Z, Agarwal J, Kung AL, Armstrong SA. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment. Leukemia. 22: 66-77. PMID 17851551 DOI: 10.1038/Sj.Leu.2404951 |
0.421 |
|
| 2008 |
Kvinlaug BT, Chan W, Bullinger L, Sears C, Paul D, Okabe R, Lee BH, De Silva I, Armstrong S, Dohner H, Gilliland DG, Huntly BJ. Common Self-Renewal Pathways Contribute to the Induction of Acute Myeloid Leukemias Associated with Different Oncogenes Blood. 112: 505-505. DOI: 10.1182/Blood.V112.11.505.505 |
0.419 |
|
| 2008 |
Stam RW, Den Boer ML, Schneider P, de Boer J, Hagelstein J, Sallan SE, Brady HJ, Armstrong S, Pieters R. Rearranged Infant Acute Lymphoblastic Leukemia. Blood. 112: 1913-1913. DOI: 10.1182/Blood.V112.11.1913.1913 |
0.356 |
|
| 2007 |
Faber J, Armstrong SA. Defining leukemia stem cells in MLL-translocated leukemias: implications for novel therapeutic strategies. Klinische Pã¤Diatrie. 219: 306-11. PMID 18050039 DOI: 10.1055/S-2007-985878 |
0.425 |
|
| 2007 |
Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development Nature Reviews Cancer. 7: 823-833. PMID 17957188 DOI: 10.1038/Nrc2253 |
0.465 |
|
| 2007 |
Faber J, Armstrong SA. Mixed lineage leukemia translocations and a leukemia stem cell program. Cancer Research. 67: 8425-8. PMID 17875678 DOI: 10.1158/0008-5472.Can-07-0972 |
0.397 |
|
| 2007 |
Stubbs MC, Armstrong SA. FLT3 as a therapeutic target in childhood acute leukemia Current Drug Targets. 8: 703-714. PMID 17584026 DOI: 10.2174/138945007780830782 |
0.369 |
|
| 2007 |
Stubbs MC, Armstrong SA. Therapeutic implications of leukemia stem cell development Clinical Cancer Research. 13: 3439-3442. PMID 17575205 DOI: 10.1158/1078-0432.Ccr-06-3090 |
0.406 |
|
| 2007 |
Wang Y, Armstrong SA. Genome-Wide SNP Analysis in Cancer: Leukemia Shows the Way Cancer Cell. 11: 308-309. PMID 17418407 DOI: 10.1016/J.Ccr.2007.03.017 |
0.351 |
|
| 2007 |
Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Macconnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, ... ... Armstrong SA, et al. High-throughput oncogene mutation profiling in human cancer. Nature Genetics. 39: 347-51. PMID 17293865 DOI: 10.1038/Ng1975 |
0.307 |
|
| 2007 |
Tothova Z, Kollipara R, Huntly BJ, Lee BH, Castrillon DH, Cullen DE, McDowell EP, Lazo-Kallanian S, Williams IR, Sears C, Armstrong SA, Passegué E, DePinho RA, Gilliland DG. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell. 128: 325-39. PMID 17254970 DOI: 10.1016/J.Cell.2007.01.003 |
0.383 |
|
| 2007 |
Tissing WJE, Den Boer ML, Meijerink JPP, Menezes RX, Swagemakers S, Van Der Spek PJ, Sallan SE, Armstrong SA, Pieters R. Genomewide identification of prednisolone-responsive genes in acute lymphoblastic leukemia cells Blood. 109: 3929-3935. PMID 17218380 DOI: 10.1182/Blood-2006-11-056366 |
0.406 |
|
| 2007 |
Faber J, Krivtsov A, Stubbs M, Wright R, van den Heuvel-Eibrink M, Kung A, Zwaan C, Armstrong S. Suppression of HOX A cluster genes inhibits proliferation and induces cell death in human mixed-lineage leukemias Journal of Clinical Oncology. 25: 14020-14020. DOI: 10.1200/Jco.2007.25.18_Suppl.14020 |
0.448 |
|
| 2007 |
Faber J, Krivstov AV, Stubbs MC, van den Heuvel-Eibrink M, Kung AL, Zwaan CM, Armstrong SA. The Myocyte Enhancer Factor 2C (MEF2C) Is a Direct Transcriptional Target of HOXA9 and Mediates Leukemia Survival in Human Mixed-Lineage Leukemias. Blood. 110: 58-58. DOI: 10.1182/Blood.V110.11.58.58 |
0.482 |
|
| 2007 |
Stubbs MC, Faber J, Kung AL, Cameron S, Armstrong SA. HOXA9 Represses Bim Expression in MLL Rearranged Leukemia: Implications for Drug Therapy. Blood. 110: 57-57. DOI: 10.1182/Blood.V110.11.57.57 |
0.488 |
|
| 2007 |
Krivtsov AV, Feng Z, Lemieux M, Faber J, Xia X, Kung AL, Armstrong SA. Global Increase in H3K79 Dimethylation in Murine and Human MLL-AF4 Lymphoblastic Leukemias. Blood. 110: 344-344. DOI: 10.1182/Blood.V110.11.344.344 |
0.46 |
|
| 2007 |
Wang Y, Krivtsov A, Losyev G, Armstrong SA. Hoxa9+Meis1a Efficiently Transform Hematopoietic Stem Cells but Not Committed Progenitors. Blood. 110: 3375-3375. DOI: 10.1182/Blood.V110.11.3375.3375 |
0.46 |
|
| 2006 |
Sears C, Armstrong SA. Microarrays to Identify New Therapeutic Strategies for Cancer Advances in Cancer Research. 96: 51-74. PMID 17161676 DOI: 10.1016/S0065-230X(06)96003-5 |
0.305 |
|
| 2006 |
Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, Stam RW, Opferman JT, Sallan SE, den Boer ML, Pieters R, Golub TR, Armstrong SA. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell. 10: 331-42. PMID 17010674 DOI: 10.1016/J.Ccr.2006.09.006 |
0.402 |
|
| 2006 |
Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (New York, N.Y.). 313: 1929-35. PMID 17008526 DOI: 10.1126/Science.1132939 |
0.304 |
|
| 2006 |
Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, Levine JE, Wang J, Hahn WC, Gilliland DG, Golub TR, Armstrong SA. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 442: 818-22. PMID 16862118 DOI: 10.1038/Nature04980 |
0.417 |
|
| 2006 |
Stam RW, den Boer ML, Passier MMCJ, Janka-Schaub GE, Sallan SE, Armstrong SA, Pieters R, Campbell M, Felice M, Ferster A, Hann I, Vora A, Hovi L, Janka-Schaub G, Li CK, et al. Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia Leukemia. 20: 264-271. PMID 16357833 DOI: 10.1038/Sj.Leu.2404074 |
0.403 |
|
| 2006 |
Faber J, Krivtsov AV, Stubbs MC, Wright R, Heuvel-Eibrink Mvd, Kung AL, Zwaan CM, Armstrong SA. HoxA9 Knockdown Inhibits Proliferation and Induces Cell Death in Human MLL-Rearranged Leukemias. Blood. 108: 734-734. DOI: 10.1182/Blood.V108.11.734.734 |
0.45 |
|
| 2006 |
Krivtsov AV, Stubbs MC, Wright R, Feng Z, Kung AL, Armstrong SA. MLL-AF9 Initiates Leukemia from a Single Committed Hematopoietic Progenitor. Blood. 108: 2534-2534. DOI: 10.1182/Blood.V108.11.2534.2534 |
0.458 |
|
| 2006 |
Stubbs MC, Kim T, Krivtsov A, Atadja P, Armstrong SA, Kung AL. Induction of Bim Facilitates Apoptosis in Leukemia Cells Treated with HDAC Inhibitors. Blood. 108: 1994-1994. DOI: 10.1182/Blood.V108.11.1994.1994 |
0.463 |
|
| 2005 |
Maia S, Haining WN, Ansén S, Xia Z, Armstrong SA, Seth NP, Ghia P, den Boer ML, Pieters R, Sallan SE, Nadler LM, Cardoso AA. Gene expression profiling identifies BAX-delta as a novel tumor antigen in acute lymphoblastic leukemia. Cancer Research. 65: 10050-8. PMID 16267031 DOI: 10.1158/0008-5472.Can-05-1574 |
0.406 |
|
| 2005 |
Armstrong SA, Look AT. Molecular genetics of acute lymphoblastic leukemia Journal of Clinical Oncology. 23: 6306-6315. PMID 16155013 DOI: 10.1200/Jco.2005.05.047 |
0.394 |
|
| 2005 |
Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E, Berger R, Clark JJ, Willis SG, Nguyen KT, Flores NJ, Estey E, Gattermann N, Armstrong S, Look AT, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. 106: 3377-9. PMID 16081687 DOI: 10.1182/Blood-2005-05-1898 |
0.357 |
|
| 2005 |
Stam RW, den Boer ML, Schneider P, Nollau P, Horstmann M, Beverloo HB, van der Voort E, Valsecchi MG, de Lorenzo P, Sallan SE, Armstrong SA, Pieters R. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood. 106: 2484-90. PMID 15956279 DOI: 10.1182/Blood-2004-09-3667 |
0.374 |
|
| 2005 |
Wang J, Iwasaki H, Krivtsov A, Febbo PG, Thorner AR, Ernst P, Anastasiadou E, Kutok JL, Kogan SC, Zinkel SS, Fisher JK, Hess JL, Golub TR, Armstrong SA, Akashi K, et al. Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. The Embo Journal. 24: 368-81. PMID 15635450 DOI: 10.1038/Sj.Emboj.7600521 |
0.431 |
|
| 2005 |
Krivstov AV, Twomey D, Feng Z, Stubbs MC, Golub TR, Armstrong SA. MLL-Fusion Proteins Induce a Stem Cell Program in Committed Progenitors To Generate Leukemia Stem Cells. Blood. 106: 465-465. DOI: 10.1182/Blood.V106.11.465.465 |
0.467 |
|
| 2005 |
Stubbs MC, Krivtsov A, Kim Y, Wright RD, Feng Z, Agarwal J, Kung AL, Armstrong SA. MLL-AF9 and FLT3 Cooperation during Myeloid Leukemogenesis: Development of a Model for Rapid Testing of New Therapeutics. Blood. 106: 1605-1605. DOI: 10.1182/Blood.V106.11.1605.1605 |
0.411 |
|
| 2005 |
Armstrong SA, Wei G, Lamb J, Opferman J, Twomey D, Stam R, den Boer M, Sallan SE, Pieters R, Golub TR. A Gene Expression Connectivity Map Identifies Rapamycin as a Glucocorticoid Resistance Reversal Agent in Lymphoblastic Leukemia. Blood. 106: 108-108. DOI: 10.1182/Blood.V106.11.108.108 |
0.401 |
|
| 2004 |
Armstrong SA, Mabon ME, Silverman LB, Li A, Gribben JG, Fox EA, Sallan SE, Korsmeyer SJ. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood. 103: 3544-6. PMID 14670924 DOI: 10.1182/Blood-2003-07-2441 |
0.348 |
|
| 2004 |
Stam RW, Den Boer ML, Passier M, Sallan SE, Armstrong SA, Pieters P. MLL Rearranged Infant Acute Lymphoblastic Leukemia Is Characterized by Silencing of the Putative Tumor Suppressor Gene FHIT. Blood. 104: 525-525. DOI: 10.1182/Blood.V104.11.525.525 |
0.34 |
|
| 2004 |
Armstrong SA. Leukemia gene expression: MLL rearrangements in AML and ALL Blood. 104: 3423-3424. DOI: 10.1182/Blood-2004-09-3504 |
0.399 |
|
| 2003 |
Armstrong SA, Golub TR, Korsmeyer SJ. MLL-rearranged leukemias: insights from gene expression profiling. Seminars in Hematology. 40: 268-73. PMID 14582077 DOI: 10.1016/S0037-1963(03)00196-3 |
0.424 |
|
| 2003 |
Armstrong SA, Korsmeyer SJ. Comparison of human genomics and genetic models of cancer to identify novel therapeutic targets Cell Cycle (Georgetown, Tex.). 2: 408-409. PMID 12963826 DOI: 10.4161/Cc.2.5.486 |
0.301 |
|
| 2003 |
Ferrando AA, Armstrong SA, Neuberg DS, Sallan SE, Silverman LB, Korsmeyer SJ, Look AT. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood. 102: 262-8. PMID 12637319 DOI: 10.1182/Blood-2002-10-3221 |
0.415 |
|
| 2003 |
Armstrong SA, Kung AL, Mabon ME, Silverman LB, Stam RW, Den Boer ML, Pieters R, Kersey JH, Sallan SE, Fletcher JA, Golub TR, Griffin JD, Korsmeyer SJ. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell. 3: 173-83. PMID 12620411 DOI: 10.1016/S1535-6108(03)00003-5 |
0.418 |
|
| 2003 |
Stam RW, Den Boer ML, Meijerink JPP, Ebus MEG, Peters GJ, Noordhuis P, Janka-Schaub GE, Armstrong SA, Korsmeyer SJ, Pieters R. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia Blood. 101: 1270-1276. PMID 12406912 DOI: 10.1182/Blood-2002-05-1600 |
0.314 |
|
| 2002 |
Armstrong SA, Hsieh JJ, Korsmeyer SJ. Genomic approaches to the pathogenesis and treatment of acute lymphoblastic leukemias. Current Opinion in Hematology. 9: 339-44. PMID 12042709 DOI: 10.1097/00062752-200207000-00012 |
0.346 |
|
| 2001 |
Dal Cin P, Atkins L, Ford C, Ariyanayagam S, Armstrong SA, George R, Cleary A, Morton CC. Amplification of AML1 in childhood acute lymphoblastic leukemias. Genes, Chromosomes & Cancer. 30: 407-9. PMID 11241794 DOI: 10.1002/1098-2264(2001)9999:9999<::Aid-Gcc1107>3.0.Co;2-C |
0.372 |
|
| 1996 |
Willnow TE, Hilpert J, Armstrong SA, Rohlmann A, Hammer RE, Burns DK, Herz J. Defective forebrain development in mice lacking gp330/megalin. Proceedings of the National Academy of Sciences of the United States of America. 93: 8460-4. PMID 8710893 DOI: 10.1073/Pnas.93.16.8460 |
0.489 |
|
| 1995 |
Armstrong SA, Brown MS, Goldstein JL, Seabra MC. Preparation of recombinant Rab geranylgeranyltransferase and Rab escort proteins Methods in Enzymology. 257: 30-41. PMID 8583933 DOI: 10.1016/S0076-6879(95)57007-1 |
0.547 |
|
| 1995 |
Armstrong SA, Hannah VC, Goldstein JL, Brown MS. CAAX geranylgeranyl transferase transfers farnesyl as efficiently as geranylgeranyl to RhoB Journal of Biological Chemistry. 270: 7864-7868. PMID 7713879 DOI: 10.1074/Jbc.270.14.7864 |
0.517 |
|
| 1995 |
Willnow TE, Armstrong SA, Hammer RE, Herz J. Functional expression of low density lipoprotein receptor-related protein is controlled by receptor-associated protein in vivo Proceedings of the National Academy of Sciences of the United States of America. 92: 4537-4541. PMID 7538675 DOI: 10.1073/Pnas.92.10.4537 |
0.49 |
|
| 1993 |
Andres DA, Seabra MC, Brown MS, Armstrong SA, Smeland TE, Cremers FPM, Goldstein JL. cDNA cloning of component A of Rab geranylgeranyl transferase and demonstration of its role as a Rab escort protein Cell. 73: 1091-1099. PMID 8513495 DOI: 10.1016/0092-8674(93)90639-8 |
0.677 |
|
| 1993 |
Armstrong SA, Seabra MC, Südhof TC, Goldstein JL, Brown MS. cDNA cloning and expression of the alpha and beta subunits of rat Rab geranylgeranyl transferase. The Journal of Biological Chemistry. 268: 12221-9. PMID 8505342 |
0.557 |
|
| Show low-probability matches. |
